Aortic regurgitation cardiac MRI

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Aortic Regurgitation Microchapters

Home

Patient Information

Overview

Historical Pesrpective

Pathophysiology

Causes

Stages

Differentiating Aortic Regurgitation from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Cardiac Stress Test

Electrocardiogram

Chest X Ray

Echocardiography

Cardiac MRI

Treatment

Acute Aortic regurgitation

Medical Therapy
Surgery

Chronic Aortic regurgitation

Medical Therapy
Surgery

Precautions and Prophylaxis

Special Scenarios

Pregnancy
Elderly
Young Adults
End-stage Renal Disease

Case Studies

Case #1

Aortic regurgitation cardiac MRI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Aortic regurgitation cardiac MRI

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Aortic regurgitation cardiac MRI

CDC on Aortic regurgitation cardiac MRI

Aortic regurgitation cardiac MRI in the news

Blogs on Aortic regurgitation cardiac MRI

Directions to Hospitals Treating Aortic regurgitation

Risk calculators and risk factors for Aortic regurgitation cardiac MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]

Overview

Cardiac MRI may be used in the assessment of individuals with valvular heart disease among whom the evaluation of valvular stenosis, regurgitation, para- or perivalvular masses, perivalvular complications of infectious processes, or prosthetic valve disease is needed. Cardiovascular magnetic resonance (CMR) may be useful in the identification of serial changes in left ventricular volume or mass among patients with valvular dysfunction. Among patients with suboptimal echocardiograms, magnetic resonance imaging is used to to determine the severity of AR and assess left ventricular volume and function at rest.[1][2][3][4][5]

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[6]

Because of the instability of the patient, MRI is rarely employed in the acute environment.


2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Diseases (DO NOT EDIT)[7]

Diagnosis and Follow Up

Class I
"1. CMR is indicated in patients with moderate or severe AR (stages B, C, and D) and suboptimal echocardiographic images for the assessment of LV systolic function, systolic and diastolic volumes, and measurement of AR severity. (Level of Evidence: B) "

2010 ACCF/ACR/AHA/NASCI/SCMR Expert Consensus Document on Cardiovascular Magnetic Resonance (DO NOT EDIT)[8]

Cardiac MRI in Valvular Heart Disease (DO NOT EDIT)[8]

CMR may be used for assessing individuals with valvular heart disease in which evaluation of valvular stenosis, regurgitation, para- or perivalvular masses, perivalvular complications of infectious processes, or prosthetic valve disease are needed. CMR may be useful in identifying serial changes in LV volumes or mass in patients with valvular dysfunction.

2008 Focused Update Incorporated Into the 2006 ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease (DO NOT EDIT)[9]

Cardiac MRI (DO NOT EDIT)[9]

Class I
"1. Radionuclide angiography or magnetic resonance imaging is indicated for the initial and serial assessment of LV volume and function at rest in patients with AR and suboptimal echocardiograms. (Level of Evidence: B)"
Class IIa
"1. Magnetic resonance imaging is reasonable for the estimation of AR severity in patients with unsatisfactory echocardiograms. (Level of Evidence: B)"

Sources

  • 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease[9]
  • 2010 ACCF/ACR/AHA/NASCI/SCMR expert consensus document on cardiovascular magnetic resonance[8]

References

  1. Ribeiro HB, Orwat S, Hayek SS, Larose É, Babaliaros V, Dahou A; et al. (2016). "Cardiovascular Magnetic Resonance to Evaluate Aortic Regurgitation After Transcatheter Aortic Valve Replacement". J Am Coll Cardiol. 68 (6): 577–85. doi:10.1016/j.jacc.2016.05.059. PMID 27491900.
  2. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 63 (22): e57–185. doi:10.1016/j.jacc.2014.02.536. PMID 24603191.
  3. Gabriel RS, Renapurkar R, Bolen MA, Verhaert D, Leiber M, Flamm SD; et al. (2011). "Comparison of severity of aortic regurgitation by cardiovascular magnetic resonance versus transthoracic echocardiography". Am J Cardiol. 108 (7): 1014–20. doi:10.1016/j.amjcard.2011.05.034. PMID 21784393.
  4. Goffinet C, Kersten V, Pouleur AC, le Polain de Waroux JB, Vancraeynest D, Pasquet A; et al. (2010). "Comprehensive assessment of the severity and mechanism of aortic regurgitation using multidetector CT and MR". Eur Radiol. 20 (2): 326–36. doi:10.1007/s00330-009-1544-x. PMID 19652976.
  5. Debl K, Djavidani B, Buchner S, Heinicke N, Fredersdorf S, Haimerl J; et al. (2008). "Assessment of the anatomic regurgitant orifice in aortic regurgitation: a clinical magnetic resonance imaging study". Heart. 94 (3): e8. doi:10.1136/hrt.2006.108720. PMID 17686805.
  6. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F; et al. (2021). "2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 143 (5): e72–e227. doi:10.1161/CIR.0000000000000923. PMID 33332150 Check |pmid= value (help).
  7. "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary". Retrieved 4 March 2014.
  8. 8.0 8.1 8.2 American College of Cardiology Foundation Task Force on Expert Consensus Documents. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA; et al. (2010). "ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents". Circulation. 121 (22): 2462–508. doi:10.1161/CIR.0b013e3181d44a8f. PMC 3034132. PMID 20479157.
  9. 9.0 9.1 9.2 Bonow RO, Carabello BA, Chatterjee K; et al. (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Unknown parameter |month= ignored (help)

Template:WH Template:WS CME Category::Cardiology